Hatcher-Martin, J. M.
McKay, J. L.
Pybus, A. F.
Sommerfeld, B.
Howell, J. C. http://orcid.org/0000-0001-9527-4239
Goldstein, F. C.
Wood, L.
Hu, W. T.
Factor, S. A. http://orcid.org/0000-0002-0449-973X
Article History
Received: 6 December 2020
Accepted: 27 October 2021
First Online: 29 November 2021
Competing interests
: Dr. Hatcher-Martin has the following disclosures: Honoraria: Acadia, Neurocrine, Parkinson’s Foundation. Dr. McKay has the following disclosures: Consulting fees: Biocircuit Technologies. Ms. Pybus has nothing to disclose. Ms. Howell has nothing to disclose. Dr. Goldstein reports no disclosures. Dr. Wood has nothing to disclose. Dr. Hu has patent or patent-pending on CSF diagnosis of FTLD-TDP, CSF prognosis of SMA, and serological assays for COVID-19; licensed serological assays for COVID-19 to Sigma-Millipore; consulted for Biogen Inc., Fujirebio Diagnostics Inc., Apellis Pharmaceuticals, and AARP; and received research support from Fujirebio Diagnostics Inc. Dr. Factor has the following disclosures: Honoraria: Lundbeck, Teva, Sunovion, Biogen, Acadia, Neuroderm, Acorda, CereSpire. Grants: Ipsen, Medtronic, Boston Scientific, Teva, US World Meds, Sunovion Therapeutics, Vaccinex, Voyager, Jazz Pharmaceuticals, Lilly, CHDI Foundation, Michael J. Fox Foundation, Royalties: Demos, Blackwell Futura for textbooks, Uptodate Other Bracket Global LLC, CNS Ratings LLC.